ArticleJournal of dental sciences2026
C-X-C motif chemokine ligand 13 and the C-X-C motif chemokine receptor 5-c-Jun N-terminal kinase-nuclear factor kappa B-matrix metalloproteinase 9 axis in oral squamous cell carcinoma metastasis.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Metastasis is the leading cause of treatment failure in oral squamous cell carcinoma (OSCC). This study investigated the role of C-X-C motif chemokine ligand 13 (CXCL13) in OSCC metastasis and the underlying signaling mechanism. Materials and methods: Integrative transcriptomic analysis was performed using three independent OSCC datasets to identify metastasis-associated genes. CXCL13 expression was examined in OSCC tissues and highly migratory sublines. The effects of CXCL13 on cell migration were evaluated in vitro. Pathway analysis, pharmacological inhibitors, and receptor silencing were used to investigate the downstream signaling pathway. An orthotopic tongue xenograft model was used to evaluate the effect of CXCL13 knockdown on metastatic dissemination in vivo. Results: A total of 143 metastasis-associated genes were identified and were mainly enriched in extracellular matrix remodeling and invasion-related pathways. Among these genes, CXCL13 was identified as a central hub and was markedly upregulated in OSCC tissues and highly migratory sublines. CXCL13 significantly promoted OSCC cell migration. Mechanistically, CXCL13 activated C-X-C motif chemokine receptor 5 (CXCR5)-dependent c-Jun N-terminal kinase (JNK) signaling, which subsequently induced nuclear factor kappa B (NF-κB) activation and matrix metalloproteinase 9 (MMP9) expression. Pharmacological inhibition of JNK or NF-κB abolished CXCL13-induced migration. In vivo, CXCL13 knockdown significantly reduced metastatic dissemination without affecting primary tumor growth. Conclusion: CXCL13 acts as a metastasis-associated regulator in OSCC and promotes tumor progression through the CXCL13-CXCR5-JNK-NF-κB-MMP9 axis. This signaling pathway may serve as a potential therapeutic target for limiting metastatic progression in OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.